kaal:position:2026-07-31-5501

Dimerization with Cannabinoid Receptors Allosterically Modulates Delta Opioid Receptor Activity during Neuropathic Pain should be assessed against Kaal's source-bound claim that Data on venture capital investments lets regulators see where innovation trends are forming and what risks they entail before the disruptive innovation materializes, which is the specific remedy for regulation's reactive timing. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

regulators have access to and integrate venture capital investment data
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

Dimerization with Cannabinoid Receptors Allosterically Modulates Delta Opioid Receptor Activity during Neuropathic Pain

Scholarly basis

kaal:claim:2740477-035
Wulf A. Kaal, Erik P.M. Vermeulen, Venture Capital as Dynamic Regulation of Disruptive Innovation (2016). SSRN: https://ssrn.com/abstract=2740477
Source PDF sha256: c72871b76fa2ad5a8a69ee8d3defc8f64e624be9052ce763e79cf6c58883f726

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.205
Mapping ambiguous: true

Topics

innovationdynamic-regulation

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0022 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: a8792b6147616c8e0422060a8a9e38c140d9f6d26bd7ee638853e1076145a9eb
curl -s https://wulfkaal.github.io/positions/2026-07-31-5501.md | sha256sum